Tweet fijado

Everything remains on track, including the closing of our merger and the forthcoming announcement of our Nasdaq partnership. While September was a period of significant activity, October will bring the full scope of our progress to light.
We sincerely thank you for your continued trust and patience as we remain focused on developing products designed to make a lasting, positive impact on the world.
Our EvoBiologics product line is now being distributed at an all-time high, significantly surpassing internal expectations. As we finalize our merger with REVIVE, we anticipate 2025 revenues to exceed $14 million USD, with projected revenues well over double in 2026. Additional revenue streams will be launched in Q4 2025 and into early 2026.
As always, more detailed updates will follow shortly via press release. $KOAN
English
